 Connection
Cecilia Low Wang to Treatment Outcome
This is a "connection" page, showing publications Cecilia Low Wang has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.221 |
|
|
|
-
Low Wang CC, Everett BM, Burman KD, Wilson PWF. Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs? Circulation. 2019 04 02; 139(14):1741-1743.
Score: 0.064
-
Low Wang CC, Blomster JI, Heizer G, Berger JS, Baumgartner I, Fowkes FGR, Held P, Katona BG, Norgren L, Jones WS, Lopes RD, Olin JW, Rockhold FW, Mahaffey KW, Patel MR, Hiatt WR. Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral?Artery Disease: The EUCLID Trial. J Am Coll Cardiol. 2018 12 25; 72(25):3274-3284.
Score: 0.063
-
Rogers RK, Hiatt WR, Patel MR, Shishehbor MH, White R, Khan ND, Bhalla NP, Jones WS, Low Wang CC. Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution. Vasc Med. 2018 12; 23(6):513-522.
Score: 0.060
-
Hsia E, Seggelke S, Gibbs J, Hawkins RM, Cohlmia E, Rasouli N, Wang C, Kam I, Draznin B. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab. 2012 Sep; 97(9):3132-7.
Score: 0.020
-
Hess CN, Low Wang CC, Hiatt WR. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. Annu Rev Med. 2018 01 29; 69:133-145.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|